340Bwell presented research at two major global HIV/AIDS conferences that addresses critical gaps in HIV prevention and treatment, with findings that could significantly alter how sexually transmitted disease clinics operate and deliver care. At the Fast Track City Conference in Paris, the company highlighted a stark geographical imbalance in Pre-Exposure Prophylaxis retention research, revealing that over 50% of studies originate from the United States, followed distantly by South Africa and Kenya. This disparity underscores an urgent need for more diverse global data to inform effective PrEP strategies worldwide.
The company's Managing Partner, Mark Erwin, introduced an innovative telehealth model for PrEP service delivery at the same conference, utilizing in-house assembled testing kits to reduce costs and expand access in resource-limited settings. This approach represents a potential paradigm shift for delivering HIV prevention services where traditional clinic-based models face logistical and financial barriers. Simultaneously, at the HIV4Prevention Conference in Lima, 340Bwell presented two posters with direct implications for clinic efficiency.
One poster demonstrated statistically significant associations between client attendance and specific appointment factors, including day of week, time slot, and whether the appointment was conducted in-clinic or via telehealth. The second poster showcased a machine learning model capable of predicting client attendance using routine clinic data. These findings address the persistent challenge of high no-show rates at PrEP clinics, which result in missed opportunities for patient engagement and wasted clinic resources.
The research is grounded in analysis of client demographic and clinical data from leading STD clinics in the United States, reflecting 340Bwell's commitment to evidence-based decision-making. Erwin emphasized the value of presenting at these global platforms, noting the importance of collaborating with international researchers and advocates working toward reducing HIV's impact. The company's work focuses on practical, implementable solutions rather than theoretical frameworks, offering immediate applications for clinics struggling with operational inefficiencies.
By addressing fundamental aspects of clinic management—appointment scheduling, service delivery models, and retention strategies—340Bwell's research provides tools that could enhance patient care while optimizing limited resources. As the global community continues working toward ending the HIV/AIDS epidemic, such data-driven approaches will be essential for translating prevention science into effective clinical practice. The findings not only offer current solutions but also establish methodologies for future research and development in HIV prevention strategies. For additional details on their work, visit https://340bwell.com/.
